{
    "clinical_study": {
        "@rank": "146273", 
        "arm_group": {
            "arm_group_label": "ESS505", 
            "arm_group_type": "Experimental", 
            "description": "All subjects who sign the informed consent and meet the eligibility critieria will be scheduled for an insert placement procedure"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and long-term (approximately one year) effectiveness of the Essure\n      System for Permanent Birth Control ESS505 device in preventing pregnancy."
        }, 
        "brief_title": "The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Contraception", 
        "detailed_description": {
            "textblock": "This study has previously been posted by Conceptus, Inc. After acquiring Conceptus, Inc.,\n      Bayer is now the sponsor of the trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female with age range 21 to 44 years\n\n          -  Subjects who are seeking permanent contraception\n\n          -  Subjects with body weight within range of 40 - 136 kilograms (90-300 pounds)\n\n          -  Subjects willing to accept the risk of pregnancy occurring while relying solely on\n             the ESS505 as contraception\n\n          -  Subjects for whom medical history and physical examination indicates bilateral viable\n             and patent fallopian tubes\n\n          -  Subjects who are able to comply with the protocol required follow-up visits (e.g., 3\n             month clinic visit, and the 12-month telephone interview)\n\n          -  Subjects who provide written informed consent prior to enrolment\n\n          -  Subjects who have sufficient mental capability to provide clinically relevant and\n             reliable feedback regarding her experience wearing the device\n\n          -  Subjects agrees that her anonymised personal data will be made available to Study\n             sponsor, requisite regional and international regulatory bodies\n\n          -  Subjects for whom there are no contraindications for use as described in the ESS505\n             Instructions for Use (IFU)\n\n        Exclusion Criteria:\n\n          -  Subjects with known proximal tubal occlusion in either fallopian tube\n\n          -  Subjects who have undergone fallopian tube sterilization procedure\n\n          -  Subjects diagnosed with unicornuate uterus\n\n          -  Subjects diagnosed with endometrial or myometrial pathology which may prevent\n             fallopian tube ostia assessment\n\n          -  Subjects scheduled to undergo concomitant intrauterine procedures at the time of\n             ESS505 placement; IUD removal is not considered a concomitant procedure\n\n          -  Subjects suspected of being or confirmed pregnant\n\n          -  Subjects post-partum or has undergone pregnancy termination \u22646 weeks of scheduled\n             ESS505 placement\n\n          -  Subjects diagnosed with active upper or lower pelvic infection\n\n          -  Subjects for whom there are one or more contraindications for use as described in the\n             ESS505 IFU\n\n          -  Subjects have positive pre-procedure pregnancy test"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861886", 
            "org_study_id": "16972", 
            "secondary_id": "ESS505-003"
        }, 
        "intervention": {
            "arm_group_label": "ESS505", 
            "description": "bilateral insert placement, single arm, open label", 
            "intervention_name": "ESS505 (BAY1454033)", 
            "intervention_type": "Device", 
            "other_name": "Essure System for Permanent Birth Control Model ESS505"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Birth control", 
            "Permanent Contraception"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hoofddorp", 
                        "country": "Netherlands", 
                        "zip": "2134 TM"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "zip": "3435 CM"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tiel", 
                        "country": "Netherlands", 
                        "zip": "4002 WP"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands", 
                        "zip": "8025 AB"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain", 
                        "zip": "14004"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Centre Clinical Study to Evaluate the Safety and Effectiveness of the ESS505\u00ae Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Netherlands: Dutch Health Care Inspectorate"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint to be evaluated in this study is occurrence of pregnancy at the 3 month visit in women told to relay on ESS505 for contraception. Absence of pregnancy is confirmed by a urine or blood pregnancy test.", 
            "measure": "Occurence of Pregnancy", 
            "safety_issue": "No", 
            "time_frame": "3 months post placement of ESS505"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861886"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "One year effectiveness rate; methods to calculate rates and confidence intervals will be identical to that described for the primary endpoint.", 
                "measure": "One Year Effectiveness Rate", 
                "safety_issue": "No", 
                "time_frame": "12 months post ESS505 placement"
            }, 
            {
                "description": "Assess severity and frequency of reported adverse events related to device placement procedure", 
                "measure": "Safety of the ESS505 Device Placement Procedure", 
                "safety_issue": "Yes", 
                "time_frame": "Day of placement of ESS505"
            }, 
            {
                "description": "Assess severity and and frequency of adverse events reported among subjects in whom one or more ESS505 inserts are placed", 
                "measure": "Safety of Subsequent Wearing of the Device", 
                "safety_issue": "Yes", 
                "time_frame": "12 months post ESS505 placement"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}